EIB Invests €100 Million in Orion Pharma to Strengthen Europe’s Drug Security

In a major boost to Europe's life sciences sector, the European Investment Bank (EIB) has announced a €100 million financing agreement with Finnish pharmaceutical company Orion Pharma to advance the development of innovative treatments for cancer, chronic pain, and other severe diseases with limited therapeutic options.

The investment underscores the European Union's growing focus on strengthening its biopharmaceutical innovation ecosystem while ensuring secure and resilient access to critical medicines.

Driving Innovation in High-Impact Therapeutic Areas

The EIB financing will directly support Orion Pharma's research and development (R&D) programmes across its European facilities. The funding will cover a broad spectrum of activities, including clinical trials, highly skilled personnel, intellectual property development, and the acquisition of advanced laboratory technologies.

This comprehensive support is expected to accelerate the company's drug development pipeline, particularly in areas where unmet medical needs remain high. Cancer and chronic pain—two of the most pressing global health challenges—continue to demand innovative therapies, with millions of patients worldwide lacking effective treatment options.

By enabling faster and more robust R&D efforts, the initiative aims to shorten the time from scientific discovery to patient access, a critical factor in improving health outcomes.

Strengthening Europe's Position in Global Biopharma

The agreement comes at a time when Europe is seeking to reinforce its competitiveness in the global pharmaceutical industry, which is increasingly dominated by large-scale innovation hubs in the United States and Asia.

EIB Vice-President Karl Nehammer emphasized the strategic importance of the investment, stating: "Europe's strength lies in its ability to turn world-class science into real-world impact. By supporting Orion Pharma's research pipeline, we are strengthening Europe's pharmaceutical industry, improving access to critical medicines and ultimately delivering better outcomes for patients."

The financing is aligned with broader EU priorities to foster high-value innovation, support knowledge-based industries, and maintain leadership in cutting-edge medical research.

Enhancing Supply Security for Critical Medicines

Beyond innovation, the project also addresses a key vulnerability exposed in recent years: Europe's dependence on external suppliers for essential medicines and active pharmaceutical ingredients (APIs).

Orion Pharma plays a significant role in this domain as a producer of APIs and an active participant in the EU's Critical Medicines Alliance—an initiative designed to secure supply chains and reduce reliance on non-European sources.

By strengthening Orion's R&D and production capabilities, the EIB investment contributes to building a more resilient pharmaceutical supply chain within Europe. This is particularly crucial in the context of global disruptions, geopolitical tensions, and rising demand for essential drugs.

A Long-Standing Partnership for Growth and Innovation

This marks the fifth project supported by the EIB Group in collaboration with Orion Pharma, reflecting a strong and ongoing partnership focused on advancing healthcare innovation and industrial capability.

René Lindell, Chief Financial Officer of Orion Pharma, highlighted the importance of the funding for the company's long-term vision: "We are pleased with the continued support from the European Investment Bank. This financing commitment will support our R&D efforts that are fundamental to our growth strategy and to our mission to build well-being."

The investment is expected to not only enhance Orion's research capabilities but also create high-skilled jobs, foster scientific collaboration, and contribute to Europe's broader innovation landscape.

Building a Health-Resilient and Innovation-Driven Europe

The €100 million financing aligns with the EU's strategic pillars of health resilience, industrial competitiveness, and technological sovereignty. As the demand for advanced therapies continues to grow, investments in pharmaceutical R&D are becoming increasingly critical for both public health and economic stability.

With this initiative, the EIB reinforces its role as a key enabler of innovation-driven growth, supporting companies that are at the forefront of tackling some of the most complex health challenges of our time.

As Europe continues to navigate an evolving healthcare landscape, partnerships like this are set to play a defining role in shaping a future where cutting-edge science translates into accessible, life-saving treatments.